Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04184115 · ClinicalTrials.gov registry record · Phase 3
Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness
A Phase 3 study, sponsored by Repurposed Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 102
- Enrollment target
NCT04184115 is a Phase 3 study that has completed, run by Repurposed Therapeutics. The registered enrollment target is 102 participants.
The verdict
NCT04184115, a Phase 3 study, has completed, sponsored by Repurposed Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 102 participants
- Enrollment target
Study Summary
Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study to identify the safety, efficacy and pharmacokinetics of a repeated-dose regimen of DPI 386 nasal gel (intranasal scopolamine gel) for the prevention and treatment of nausea associated with motion sickness.
Interventions
- DRUG Placebos
- DRUG DPI-386 Nasal Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2019-06-09 |
| Est. Completion | 2019-06-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04184115
The ClinicalTrials.gov registry entry for NCT04184115 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repurposed Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT04184115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04184115 about?
NCT04184115 is a clinical study titled "Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness". Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study to identify the safety, efficacy and pharmacokinetics of a repeated-dose regimen of DPI 386 nasal gel (intranasal scopolamine gel) for the prevention and treatment of nausea associated with motion sickness.
What is the current status of trial NCT04184115?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2019-06-09. Estimated completion is 2019-06-11.
What interventions are being tested in trial NCT04184115?
The interventions under investigation include: Placebos (DRUG), DPI-386 Nasal Gel (DRUG).
Who is sponsoring clinical trial NCT04184115?
This trial is sponsored by Repurposed Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.